Seroatlas · Human Serome Atlas

MSH3

DNA mismatch repair protein Msh3

Also known as: DUP, MRP1, MSH3_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P20585
Gene: MSH3
Ensembl: ENSG00000113318
Chromosome: 5
Canonical length: 1137 aa
Protein class: Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins
Subcellular location: Nuclear bodies

OverviewNCBI Gene

The protein encoded by this gene forms a heterodimer with MSH2 to form MutS beta, part of the post-replicative DNA mismatch repair system. MutS beta initiates mismatch repair by binding to a mismatch and then forming a complex with MutL alpha heterodimer. This gene contains a polymorphic 9 bp tandem repeat sequence in the first exon. The repeat is present 6 times in the reference genome sequence and 3-7 repeats have been reported. Defects in this gene are a cause of susceptibility to endometrial cancer. [provided by RefSeq, Mar 2011]

Canonical amino-acid sequenceUniProt

1137 residues, UniProt reviewed canonical sequence.

>P20585|MSH3
     1  MSRRKPASGG LAASSSAPAR QAVLSRFFQS TGSLKSTSSS TGAADQVDPG AAAAAAAAAA
    61  AAPPAPPAPA FPPQLPPHIA TEIDRRKKRP LENDGPVKKK VKKVQQKEGG SDLGMSGNSE
   121  PKKCLRTRNV SKSLEKLKEF CCDSALPQSR VQTESLQERF AVLPKCTDFD DISLLHAKNA
   181  VSSEDSKRQI NQKDTTLFDL SQFGSSNTSH ENLQKTASKS ANKRSKSIYT PLELQYIEMK
   241  QQHKDAVLCV ECGYKYRFFG EDAEIAAREL NIYCHLDHNF MTASIPTHRL FVHVRRLVAK
   301  GYKVGVVKQT ETAALKAIGD NRSSLFSRKL TALYTKSTLI GEDVNPLIKL DDAVNVDEIM
   361  TDTSTSYLLC ISENKENVRD KKKGNIFIGI VGVQPATGEV VFDSFQDSAS RSELETRMSS
   421  LQPVELLLPS ALSEQTEALI HRATSVSVQD DRIRVERMDN IYFEYSHAFQ AVTEFYAKDT
   481  VDIKGSQIIS GIVNLEKPVI CSLAAIIKYL KEFNLEKMLS KPENFKQLSS KMEFMTINGT
   541  TLRNLEILQN QTDMKTKGSL LWVLDHTKTS FGRRKLKKWV TQPLLKLREI NARLDAVSEV
   601  LHSESSVFGQ IENHLRKLPD IERGLCSIYH KKCSTQEFFL IVKTLYHLKS EFQAIIPAVN
   661  SHIQSDLLRT VILEIPELLS PVEHYLKILN EQAAKVGDKT ELFKDLSDFP LIKKRKDEIQ
   721  GVIDEIRMHL QEIRKILKNP SAQYVTVSGQ EFMIEIKNSA VSCIPTDWVK VGSTKAVSRF
   781  HSPFIVENYR HLNQLREQLV LDCSAEWLDF LEKFSEHYHS LCKAVHHLAT VDCIFSLAKV
   841  AKQGDYCRPT VQEERKIVIK NGRHPVIDVL LGEQDQYVPN NTDLSEDSER VMIITGPNMG
   901  GKSSYIKQVA LITIMAQIGS YVPAEEATIG IVDGIFTRMG AADNIYKGQS TFMEELTDTA
   961  EIIRKATSQS LVILDELGRG TSTHDGIAIA YATLEYFIRD VKSLTLFVTH YPPVCELEKN
  1021  YSHQVGNYHM GFLVSEDESK LDPGAAEQVP DFVTFLYQIT RGIAARSYGL NVAKLADVPG
  1081  EILKKAAHKS KELEGLINTK RKRLKYFAKL WTMHNAQDLQ KWTEEFNMEE TQTSLLH

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against MSH3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.34
Highest tissue expression: 12 nTPM

Expression across tissuesHPA

Tissue

kidney: 12 nTPM
liver: 11 nTPM
thyroid gland: 10 nTPM
adipose tissue: 8.8 nTPM
parathyroid gland: 8.2 nTPM
fallopian tube: 6.7 nTPM

Single-cell type

adipocytes: 264 nCPM
neutrophil progenitors: 238 nCPM
proximal tubule cells: 193 nCPM
thyrotrophs: 193 nCPM
corticotrophs: 188 nCPM
lactotrophs: 185 nCPM

Immune cell

T-reg: 4.8 nTPM
non-classical monocyte: 4.7 nTPM
MAIT T-cell: 3.8 nTPM
memory CD8 T-cell: 3.6 nTPM
memory CD4 T-cell: 3.5 nTPM
gdT-cell: 3.4 nTPM

Brain region

thalamus: 5.6 nTPM
basal ganglia: 5.1 nTPM
hypothalamus: 5 nTPM
spinal cord: 4.8 nTPM
midbrain: 4.3 nTPM
cerebral cortex: 4.2 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about MSH3.

Disease | AllUniProt

Conditions MSH3 is implicated in, by any mechanism.

Endometrial cancer (ENDMC) MIM:608089
Familial adenomatous polyposis 4 (FAP4) MIM:617100

Disease | GeneticClinVar

605 pathogenic / likely-pathogenic of 5,358 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Familial adenomatous polyposis 4
Hereditary cancer-predisposing syndrome
Endometrial carcinoma
MSH3-related disorder
Neoplasm

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.16
gnomAD pLI: 0
gnomAD missense Z: -0.8
DepMap mean gene effect: -0.07
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of MSH3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads MSH3 as an antibody target. Whether an autoantibody or antibody against MSH3 could matter depends on whether native MSH3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

MSH3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label MSH3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...